SCHEMBL282483

SCHEMBL282483

N#Cc1ccc(F)c(C(=O)Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
ALOX15 P16050 1/20 0.47
GRM5 P41594 2/20 0.43
VNN1 O95497 1/20 0.43
TRPA1 O75762 2/20 0.42
MAP2K1 Q02750 1/20 0.40
P4HB P07237 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KAT6A Q92794 1/20 0.40
HSD17B14 Q9BPX1 1/20 0.40
HTT P42858 2/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
NLRP3 Q96P20 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
FLT1 P17948 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646582 0.85 KMT2A (0.49) ALDH1A1ALOX15TRPA1MAP2K1P4HB
SCHEMBL30361968 0.83 MAP2K1 (0.51) GRM5VNN1TRPA1MAP2K1P4HB
SCHEMBL284291 0.83 MAP2K1 (0.51) GRM5VNN1TRPA1MAP2K1P4HB
SCHEMBL29726442 0.81 CASP1 (0.44) ALDH1A1GRM5VNN1TRPA1MAP2K1
SCHEMBL923754 0.81 CASP1 (0.44) ALDH1A1GRM5VNN1TRPA1MAP2K1
SCHEMBL7213897 0.81 GRM5 (0.46) ALDH1A1GRM5VNN1TRPA1MAP2K1
SCHEMBL1692766 0.81 GRM5 (0.49) ALDH1A1GRM5VNN1TRPA1MAP2K1
SCHEMBL21056017 0.79 VCAM1 (0.47) ALDH1A1HTTLMNAMAPTTSHR
Hydrochloric Acid SCHEMBL15190391 0.79 CA1 (0.47) ALDH1A1GRM5VNN1TRPA1MAP2K1
SCHEMBL7951890 0.78 TTR (0.39) ALDH1A1MAP2K1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025098515-A1 HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2025-05-15 WO disclosed
WO-2025082533-A1 FUSED-RING COMPOUNDS, PREPARATION THEREFOR AND USE THEREOF 上海轶诺药业有限公司 2025-04-24 WO disclosed
WO-2024028169-A1 NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-02-08 WO disclosed
CN-111630030-B Novel benzamide derivatives as PPAR-gamma modulators 梅迪比奥法尔玛公司 2023-06-20 CN disclosed
US-11267808-B2 Benzamide derivatives as PPAR-gamma modulators MEDIBIOFARMA, S.L. (ES) 2022-03-08 US disclosed
EP-3724165-B1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA S L (ES) 2022-01-12 EP disclosed
EP-3724165-B1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA S L (ES) 2022-01-12 EP disclosed
US-20210171511-A1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA, S.L. (ES) 2021-06-10 US disclosed
US-20210171511-A1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA, S.L. (ES) 2021-06-10 US disclosed
EP-3724165-A1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS MEDIBIOFARMA, S.L. (ES) 2020-10-21 EP disclosed
US-20030092677-A1 Glutamate receptor antagonists ADAM GEO (DE) 2003-05-15 US disclosed
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2003-03-20 US disclosed
US-6509328-B1 Metabotropic glutamate receptor antagonists and accordingly are useful for the treatment of a range of neurological disorders, including psychosis, schizophrenia, Alzheimer's and others HOFFMANN-LA ROCHE INC. 2003-01-21 US disclosed
WO-2002068417-A3 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS SLASSI ABDELMALIK (CA) 2002-11-14 WO disclosed
WO-2002068417-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-09-06 WO disclosed
EP-1224175-A2 BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-07-24 EP disclosed
EP-1224174-A2 BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-07-24 EP disclosed
US-6407094-B1 4-5-DIDEHYDRO-1,5-BENZODIAZEPIN-2-ONE DERIVATIVES; PSYCHOLOGICAL, NERVOUS SYSTEM, AND BRAIN DISORDERS; COGNITION ACTIVATORS; ALZHEIMER*S DISEASE, SCHIZOPHRENIA HOFFMANN-LA ROCHE INC. 2002-06-18 US disclosed
WO-2001029012-A2 BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-04-26 WO disclosed
WO-2001029011-A2 BENZODIAZEPINE DERIVATIVES AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171511-A1 NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA MODULATORS PPARD, PPARG, PPARA ALDH1A1 597/4885ALOX15 748/4885GRM5 267/4885
US-20030092677-A1 Glutamate receptor antagonists GRM1, GRM3, GRM2 ALDH1A1 637/4885ALOX15 3373/4885GRM5 12/4885
US-11267808-B2 Benzamide derivatives as PPAR-gamma modulators PPARG, PPARD, PPARA ALDH1A1 606/4885ALOX15 783/4885GRM5 270/4885
US-20030055085-A1 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists GRM2, GRIN2A, GRM1 ALDH1A1 3466/4885ALOX15 2672/4885GRM5 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.